Navigation Links
Taxotere in Medical News

Interviewed Experts Expect Taxotere to Increase Overall Survival More Than Other Drugs, Including Lupron Depot, in Stage III Prostate Cancer

A Drug That Improves Survival Would Earn a 50 Percent Patient Share in the U.S. and a 40 Percent Patient Share in Europe , According to a New Report from Decision Resources WALTHAM, Mass., April 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms ...

Free Access to Taxotere Instills New Hope among Early Stage Breast Cancer Patients

National Institute for Health and Clinical Excellence said that 10,000 breast cancer patients who are in their early stage of the disease would be given free access to// Taxotere, a chemotherapy drug. This drug was initially given to those suffering from late-stage breast cancer. Statistics sai...

FDA Gives Green Signal To Sanofi-Aventis SA's Cancer Drug Taxotere

French drug maker Sanofi-Aventis SA announced on Thursday that the US Food and Drug Administration has approved its cancer drug Taxotere to treat patients with stomach cancer.// This approval means that Taxotere can be used in combination with chemotherapy drugs cisplatin and 5-fluorouracil to trea...

Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018

..., an achievement attained only by Sanofi-Aventis's taxotere and, more recently, by the therapeutic cancer vacc...stin will be driven by its use in combination with taxotere and sales of Alpharadin will be driven by its use ...Resources Analyst Andrew Merron, Ph.D. "The use of taxotere to treat patients not previously receiving cytotox...

Drug May Extend Life When Breast Cancer Spreads

..."There has been sort of a preconceived notion that taxotere is the most potent anti-cancer therapy for metasta...h the fourth week off. The fourth group was given taxotere every three weeks at the standard dose. Abraxane was found to be generally superior to taxotere in response rates, but the most striking results w...

Sanofi-aventis Announces Good First-quarter 2009 Performance

...idra (R) SoloSTAR (R) were approved in Japan on April 22, 2009. Boosted by its use in adjuvant breast cancer treatment and in prostate cancer, taxotere (R) performed well, especially in Europe and Other Countries, where sales rose by 8.1% (to euro 231 million) and by 18.9% (to euro 106 million) resp...

ADVENTRX Grants Exclusive Rights to ANX-514 in South Korea

... and neck and gastric cancers. In 2007, the aggregate worldwide market for taxotere was in excess of $3 billion. The market for taxotere in South Korea was in excess of $30 million in 2007. "Shin Poong is we...

Sanofi-aventis Delivers 2008 Results Above Guidance

...ales growth in the United States. Our goal is to establish Lantus(R) as the leading anti-diabetic in the world by value. In the fourth quarter, taxotere (R) posted another fine performance, especially in the United States where net sales were up 16.9% at EUR 208 million, driven by the product's use i...

If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer

...he/Chugai's Drug in Combination With Herceptin and taxotere Will Become Decision Resources Gold Standard Regim... in combination with Herceptin and Sanofi Aventis' taxotere will become Decision Resources' proprietary clinic...r the indication in combination with Herceptin and taxotere in 2013. "Based on surveys and interviews we...

AstraZeneca's Drug Will Become the New Clinical Gold Standard by 2012 for the Treatment of Metastatic Hormone-Refractory Prostate Cancer

...s' optimism for zibotentan's Phase II survival data combined with our survey results make zibotentan the most likely agent to supplant Sanofi-Aventis' taxotere as our gold standard treatment for metastatic hormone-refractory prostate cancer patients," stated Natalia Reoutova, M.Sc., analyst at Decision Resour...
Taxotere in Medical Technology

ADVENTRX Announces Results From ANX-514 Bioequivalence Study

...tration, pharmaceutical equivalence of ANX-514 and taxotere was observed. The bioequivalence study of A...d, randomized, crossover comparison of ANX-514 and taxotere in patients with advanced cancer potentially sensi...ing the pharmacokinetic equivalence of ANX-514 and taxotere and determining the safety of a single dose of ANX...

ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study

...and neck & gastric cancers. In 2007, the aggregate worldwide market for taxotere was in excess of $3 billion. The study is a multi-center, open-label,...tere, with a primary endpoint of pharmacokinetic equivalence of ANX-514 and taxotere and a goal of 28 evaluable patients. The safety of a single dose of ANX-514...

Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

...ed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial i...

Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer

...zed, controlled Phase 3 clinical trial designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-rela...

Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine

...rily North American centers, patients who received taxotere added to cisplatin and 5-fluorouracil (TPF, n=255)...f Medicinal products (EMEA) of the indications for taxotere in combination with cisplatin and 5-fluorouracil f...hree cycles either with an intravenous infusion of taxotere 75 mg/m(2) plus cisplatin 100 mg/m(2) on day one a...

Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors

...el; Sanofi Aventis) in patients with solid tumors. taxotere is an approved chemotherapy agent marketed for use...cycle to patients with cancer where treatment with taxotere is approved or considered standard of care, or pat...eclinical models that MGCD0103 is synergistic with taxotere and could potentially sensitize and re-sensitize p...

Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery

...mpared to 48% in the PF arm. "The TAX 324 trial found that the addition of taxotere to standard induction chemotherapy significantly improved patient survival,...ncology Program at Dana-Farber Cancer Institute in Boston. "The approval of taxotere to be given in combination with other standard chemotherapy as the first st...

ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)

...icity was observed following dosing with ANX-514 than dosing with Taxotere. taxotere induced an anaphylactoid type reaction consistent with hypersensitivity rea...n 505(b)(2) NDA covering ANX-514, ADVENTRX must certify that all applicable taxotere patents have expired prior to the manufacture, use or sale of ANX-514. Ab...

Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association

...atin plus prednisone arm (N=351) compared with 13.8 percent for the placebo arm (N=181) (p=0.005). Pain response rates for patients treated with prior taxotere were 25.7 percent for the satraplatin arm compared with 13.1 percent for control (p<0.015). All of the findings presented today continue to build on t...

Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting

...ogression for patients receiving satraplatin. These analyses included prior taxotere use, geographies, as well as presence or absence of pain. CHICAGO, June 04...favored satraplatin for all pre- specified patient subsets, including prior taxotere use, geographies, and the presence or absence of pain. For each of the 20 s...
Taxotere in Biological News

Sunshine pill for prostate cancer in 2009

...ould be expected to take one tablet once a week with their weekly regime of taxotere for three weeks out of every four. Business analysts say Asentar is a ... the success of early trials. 'The phase II trial used a less than optimal taxotere regime so the survival rate may have been artificially inflated,' he says. ...
Taxotere in Biological Technology

The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.

...s.us or www.sanofi-aventis.com . Please see the accompanying Eloxatin (oxaliplatin injection), Lovenox (enoxaparin sodium injection), and taxotere (docetaxel) Injection Concentrate full prescribing information, including Boxed Warnings. Forward Looking Statements This press rel...

Sanofi-aventis Announces Second Quarter 2009 Results

...les of the product were up 6.9% at euro 1,542 million. No biosimilar of Lovenox ((R)) has been approved in the United States to date. taxotere ((R)) achieved second-quarter growth of 10.7% to euro 584 million, driven by its use in adjuvant breast cancer treatment and in prostate cancer. Gro...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...n Localized Prostate Cancer II-61 Balanced Intake of Omega-6 and Omega-3 Fatty Acids Found to Reduce Prostate Cancer Growth II-62 Sanofi's taxotere Gains Approval from Nice of UK for Use in Late-Stage Prostate Cancer II-62 Protox Gains Clearance from FDA to Conduct Phase I Trial of PRX...

ADVENTRX Announces Further Cost-Cutting Measures

...etaxel emulsion for injection) is a reformulation of the blockbuster chemotherapeutic agent, Taxotere(R). In 2007, the aggregate worldwide market for taxotere was in excess of $3 billion. ANX-530 (vinorelbine injectable emulsion) is a reformulation of Navelbine(R) which, despite being a generic product for ...

ADVENTRX Exploring Strategic Options

.... ANX-514 (docetaxel emulsion) is a reformulation of the blockbuster chemotherapeutic agent, Taxotere(R). In 2007, the aggregate worldwide market for taxotere was in excess of $3 billion. ANX-530 (vinorelbine emulsion) is a reformulation of Navelbine(R) which, despite being a generic product for a number of ...

First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA

...tment of HER2 (Human Epidermal growth factor Receptor 2)-positive early breast cancer. The AC-TH regimen (doxorubicin and cyclophosphamide followed by taxotere and Herceptin), also investigated in the BCIRG 006 study, received approval at the same time. Results from the BCIRG 006 clinical trial showed that ...

AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016

...e opinions of interviewed thought leaders indicate that Avastin/Taxol/Paraplatin has advantages over the sales-leading combination of Sanofi-Aventis's taxotere and Bristol-Myers Squibb's Platinol-AQ on overall survival." About the Report Non-Small-Cell Lung Cancer (Advanced): Current Gold-Standard Therapy...

ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests

... under the brand name Taxotere(R). Annual sales of taxotere in 2006 were approximately $2.2 billion. "We feel...lactoid clinical reactions were observed following taxotere administration, including decreased respiration, s...hat demonstrates the bioequivalence of ANX-514 and taxotere is sufficient clinical data to support filing an N...

Arius announces new findings in Trop-2 and CD59 CANCER antibody programs

... by up to 100 percent. Subsequent testing showed efficacy in animal models of breast, colon and prostate cancers. The antibody compared favorably with taxotere in prostate cancer model and has also shown the ability to be highly potent at low-dose concentrations. Additional information can be found at the AA...

ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference

... cancers, and is marketed under the brand name Taxotere(R). Annual sales of taxotere in 2006 were approximately $2.2 billion. ADVENTRX recently received confir...proximately 28 patients that demonstrates the bioequivalence of ANX-514 and taxotere is sufficient to support filing an NDA. About ANX-514 (docetaxel emulsion)...
Other Tags
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... the community. , Eleven physicians from Allied’s Fullerton division volunteered to help provide ... annual Super Surgery Saturday, March 21, at St. Jude Medical Center. , ...
(Date:6/30/2015)... ... June 30, 2015 , ... CCAR is pleased to announce its expansion of ... Willimantic and Bridgeport. This month, staff member Jim Higgins left his role as ... is excited to take on this role of organizing peer recovery support available through ...
(Date:6/30/2015)... ... June 30, 2015 , ... An opinion piece published May ... procedures had over breast implants when reconstructing breasts after a mastectomy. The author ... feel natural,” have increased sensation, and are less likely than implant reconstructions to ...
(Date:6/30/2015)... ... ... After more than five years of research and development that includes active ... formulated for the unique skin of all people of color — is now available. ... to help protect the skin of all people of color this July Fourth holiday ...
(Date:6/30/2015)... , ... June 30, 2015 ... ... the drug response profiling test to help oncologists provide personalized cancer treatment, ... “The CorrectChemo® assay provides the oncologist with valuable insight on how a ...
Breaking Medicine News(10 mins):Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3Health News:The Connecticut Community for Addiction Recovery takes Recovery Coaching to a new level 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3Health News:GlobalSun – The First Sunscreen Developed for All People of Color – Hits The Market 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 3
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
Other Contents